PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric et al., 2018
GLOW Stack · GHK-Cu + BPC-157
GLOW is a community / supplier name for a pre-blended vial that typically combines GHK-Cu with BPC-157 (some catalogs also include TB-500 — see Glow 70 variants). PeptIQ tracks GLOW as an educational blend so single-vial products can be searched and logged without inventing separate medical claims for the mixture. Evidence for each ingredient lives on the component pages; the blend itself is not FDA-approved.
Overall check-ins
Trackers & reports
Overview
GLOW is a community / supplier name for a pre-blended vial that typically combines GHK-Cu with BPC-157 (some catalogs also include TB-500 — see Glow 70 variants). PeptIQ tracks GLOW as an educational blend so single-vial products can be searched and logged without inventing separate medical claims for the mixture. Evidence for each ingredient lives on the component pages; the blend itself is not FDA-approved.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 38% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 50–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 43% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 282 repeat reporters
Community charts use modeled aggregates when live Supabase snapshots are unavailable.
Research
PubMed
Sikiric et al., 2018
Review Article
Pickart et al., 2018
Tools
More ways to learn about GLOW Blend from observational PeptIQ data.
Compare with
Related peptides
Help
This page summarizes 1,281 anonymized self-reports from PeptIQ users who track GLOW Blend, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. GLOW Blend is listed as Research Only. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests GLOW Blend may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceGLOW Blend is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified GLOW Blend as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of GLOW Blend have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on GLOW Blend, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source